![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
THN391, is a monoclonal antibody that is designed to selectively block fibrin-mediated neuroinflammation without interfering with fibrin’s coagulation properties, for the treatment of neurodegenerative ocular diseases.
Lead Product(s): THN391
Therapeutic Area: Ophthalmology Product Name: THN391
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 08, 2024
Details:
THN391 is a fibrin-targeting therapeutic which binds to the inflammation-driving component of fibrin that is known to activate pathological immune responses in dementia and ophthalmologic diseases.
Lead Product(s): THN391
Therapeutic Area: Neurology Product Name: THN391
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2023
Details:
THN391 is a fibrin-targeting therapeutic which binds to the inflammation-driving component of fibrin that is known to activate pathological immune responses in neurodegenerative and ophthalmologic diseases.
Lead Product(s): THN391
Therapeutic Area: Neurology Product Name: THN391
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2023
Details:
The funding will advance Therini Bio's pipeline of fibrin-targeting therapies and advance its lead antibody THN391, that binds the inflammation-driving component of fibrin that is known to activate immune responses in neurodegenerative and ophthalmologic diseases.
Lead Product(s): THN391
Therapeutic Area: Neurology Product Name: THN391
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Dementia Discovery Fund
Deal Size: $36.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing April 27, 2023